U.S. Markets close in 5 hrs 6 mins

Experts question Alzheimer's treatment strategy after Biogen failure

Allison DeAngelis
Experts question Alzheimer's treatment strategy after Biogen failure

Though some Massachusetts startups and researchers are maintaining a dogged determinedness in targeting a protein called amyloid beta, many are calling Biogen's aducanumab failure the last nail in the coffin.